Literature DB >> 8470759

Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study.

R Kodet1, W A Newton, A B Hamoudi, L Asmar, D L Jacobs, H M Maurer.   

Abstract

The pleomorphic subtype of rhabdomyosarcoma (RMS) is now rarely diagnosed in both children and adults. Most cases previously called pleomorphic RMS are probably diagnosed as something else, most often embryonal RMS in children and malignant fibrous histiocytoma in adults. To analyze the concept of pleomorphic RMS in children, we reviewed the tumors of patients entered on the Inter-group Rhabdomyosarcoma Study (IRS I, II, and III). The presence of cells with lobated, hyperchromatic nuclei at least three times larger than the common tumor cell population (anaplastic cells) was selected as the main criterion. Of about 3,000 cases, 110 showed these types of cells, had sufficient histologic material, and had available follow-up data. These tumors were divided into two subgroups: Subgroup I tumors contained only scattered anaplastic cells, and tumors with foci or large sheets of anaplastic cells were classified as subgroup II. Besides the anaplastic-pleomorphic areas, most of these tumors had distinctive features of embryonal RMS (105 cases) and rarely had characteristics of alveolar RMS (five cases). The age distribution of these patients did not differ significantly from those whose tumors did not show the anaplastic features, the average being 6 years and the median 4 years. Lower extremity, retroperitoneum, and the head and neck region were the most common primary tumor sites. The 5-year survival rate was 60% for subgroup I tumors and 45% for subgroup II tumors compared with the survival rate of 68% for 482 IRS II embryonal RMS cases with no anaplastic-pleomorphic features. The lower survival rate for patients in subgroup II was statistically significant (p = 0.004) and similar to the unfavorable survival of patients with alveolar RMS and undifferentiated sarcoma. Because anaplastic cells are seen in many soft tissue sarcomas and in both embryonal and alveolar RMS in children, this feature is not sufficiently unusual to separate a pleomorphic subtype of RMS. The presence of anaplastic cells in aggregates or diffuse sheets throughout the tumor, however, portends a poor survival for these patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8470759     DOI: 10.1097/00000478-199305000-00002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Primary renal sarcomas in the Intergroup Rhabdomyosarcoma Study Group (IRSG) experience, 1972-2005: A report from the Children's Oncology Group.

Authors:  Beverly Raney; James Anderson; Carola Arndt; Willam Crist; Harold Maurer; Stephen Qualman; Moody Wharam; Eugene Wiener; William Meyer
Journal:  Pediatr Blood Cancer       Date:  2008-09       Impact factor: 3.167

2.  Tracheal defect and embryonal rhabdomyosarcoma in a young dog.

Authors:  S R Yanoff; C Fuentealba; H W Boothe; K S Rogers
Journal:  Can Vet J       Date:  1996-03       Impact factor: 1.008

3.  Embryonal rhabdomyosarcoma of the cervix with focal pleomorphic areas.

Authors:  J P Houghton; W G McCluggage
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

Review 4.  What is new in rhabdomyosarcoma management in children?

Authors:  Yasmin Gosiengfiao; Jennifer Reichek; David Walterhouse
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.022

5.  Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass.

Authors:  P Dias; B Chen; B Dilday; H Palmer; H Hosoi; S Singh; C Wu; X Li; J Thompson; D Parham; S Qualman; P Houghton
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

6.  Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Stephen Qualman; James Lynch; Julia Bridge; David Parham; Lisa Teot; William Meyer; Alberto Pappo
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

7.  Advantage of FISH analysis using FKHR probes for an adjunct to diagnosis of rhabdomyosarcomas.

Authors:  Tadaki Matsumura; Takehiko Yamaguchi; Kunihiko Seki; Tadakazu Shimoda; Takuro Wada; Toshihiko Yamashita; Tadashi Hasegawa
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

8.  Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers.

Authors:  Simone Hettmer; Natasha M Archer; Gino R Somers; Ana Novokmet; Amy J Wagers; Lisa Diller; Carlos Rodriguez-Galindo; Lisa A Teot; David Malkin
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

9.  Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations.

Authors:  Jennifer A Bennett; Zehra Ordulu; Robert H Young; Andre Pinto; Koen Van de Vijver; Eike Burandt; Pankhuri Wanjari; Rajeev Shah; Leanne de Kock; William D Foulkes; W Glenn McCluggage; Lauren L Ritterhouse; Esther Oliva
Journal:  Mod Pathol       Date:  2021-05-20       Impact factor: 7.842

10.  The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Archana Shenoy; Elysia Alvarez; Yueh-Yun Chi; Minjie Li; Jack F Shern; Javed Khan; Susan M Hiniker; Candace F Granberg; Douglas S Hawkins; David M Parham; Lisa A Teot; Erin R Rudzinski
Journal:  Eur J Cancer       Date:  2020-12-07       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.